Storm Therapeutics Research
A Phase 2 study of STC-15 in Leiomyosarcoma & Liposarcoma — targeting cancer at a deeper biological level
STC-15 Phase 2 Clinical Trial — NCT06975293
Storm Therapeutics is actively enrolling patients with leiomyosarcoma (uterine & non-uterine) and liposarcoma into this Phase 2 study of STC-15, an oral METTL3 inhibitor. Sites are open now across the US — talk to your oncologist about eligibility.
Clinical Trial for Leiomyosarcoma & Liposarcoma Patients
Because of their cell similarities
Storm Therapeutics has opened a Phase 2 study of STC-15 in leiomyosarcoma (uterine & non-uterine). STC-15 is a METTL3 inhibitor, administered as an oral tablet monotherapy to sarcoma patients. STC-15 inhibits the differentiation of aberrant stem cells that mature into leiomyosarcoma. The study is open at three sites in the US now, with many more to come.
STORM Therapeutics Recorded Program
Watch Storm Therapeutics' recorded presentation about their novel Phase 2 clinical trial of STC-15 for leiomyosarcoma and liposarcoma patients.
🔬 What Makes This Trial Important?
This study is testing a completely new way of treating leiomyosarcoma — not just attacking the tumor, but trying to interrupt how the cancer forms and grows at a deeper level.
- STC-15 targets METTL3, which plays a role in how cells "decide" what they become.
- In LMS, some cells behave like abnormal stem cells, which can keep producing more cancer.
- This drug is designed to block that process, potentially slowing or stopping tumor growth at its source.
💡 In simple terms: Instead of just shrinking tumors, this approach may help stop the cancer from continually rebuilding itself.
💊 Why Patients Might Care About This Treatment
1. A New Mechanism — Different from Standard Chemo
Most LMS treatments (like doxorubicin) work by killing rapidly dividing cells. STC-15 works differently — it aims to reprogram or disrupt cancer cell development.
This could mean:
- Activity in patients who no longer respond to standard treatments
- A new option for difficult-to-treat disease
2. Oral Therapy — Pill Instead of IV
- Taken as a tablet, not an infusion
- May reduce time spent in clinics
- Potentially easier to fit into daily life
💊 For many patients, this is a meaningful quality-of-life benefit.
3. Focus on Leiomyosarcoma Specifically
- This trial includes both uterine and non-uterine LMS
- LMS has historically had limited targeted therapy options
❤️ That makes this study especially important — it is built for this patient community, not just borrowed from another cancer type.
📊 Why a Phase 2 Trial Matters
Phase 2 trials are where researchers start to answer:
- Does this drug actually work in this cancer?
- How well does it control disease?
- What are the side effects?
Positive results here can lead to:
- Larger Phase 3 trials
- Faster development timelines
- Potential future approval
🌍 Bigger-Picture Impact
If STC-15 is successful, it could:
- Open the door to a new class of drugs — METTL3 inhibitors
- Change how LMS is treated — shifting toward targeting cancer biology, not just tumor size
- Provide hope for more personalized and less toxic treatments
❤️ What Patients Should Realistically Keep in Mind
- This is still early-stage research
- We don't yet know how effective it will be
- Not everyone will benefit
🔬 But trials like this are how progress happens — especially in rare cancers like LMS.
Bottom Line — Patient Takeaway
This trial represents hope for a smarter, more targeted way to treat leiomyosarcoma — one that may go after the root of the cancer, not just the symptoms.
Learn More & Find Trial Sites
View full eligibility criteria, participating sites, and enrollment details on ClinicalTrials.gov
View Clinical Trial — NCT06975293